Background: There have been few reports on the outcome of extracorporeal membrane oxygenation (ECMO) in newborn Japanese infants. Methods: A review was carried out of 61 neonates with ECMO between January 1995 and December 2015 at a single center. ECMO was used in neonates with oxygenation index >20 after conventional treatment. Background factors, such as etiology, vascular access mode (veno-venous [VV] or veno-arterial [VA]), number of days with ECMO, and early ECMO (within 24 h after birth), were analyzed in relation to outcome with respect to survival to hospital discharge (SHD).
Extracorporeal membrane oxygenation (ECMO) can be used to provide temporary support during respiratory failure in newborns. This technique involves oxygenation of blood outside the body, thereby obviating the need for gas exchange in the lungs, and it can also aid cardiovascular circulation if necessary. 1 A significantly increased number of survivors was seen in two randomized trials of neonatal ECMO, 2, 3 and active ECMO support was recommended for neonates with severe but potentially reversible respiratory failure. The UK Collaborative ECMO Trial incorporated an economic evaluation into its design from the outset, and provided rigorous evidence of the costeffectiveness of neonatal ECMO over a 7 year observation period. 4 The Extracorporeal Life Support Organization (ELSO) was formed in 1989, as a group of centers using extracorporeal life support in the management of cardiopulmonary failure unresponsive to conventional medical and surgical therapy. 5 Until July 2011, nearly 51 000 patients were registered at the ELSO, and neonatal ECMO accounted for approximately 50% of all cases. 5 Given, however, that no registry system has been available in Japan, reports on the outcome of neonatal ECMO have been limited; to our knowledge, only one report is available in English addressing the outcomes of newborn Japanese infants treated with ECMO for congenital diaphragmatic hernia (CDH). 6 Accordingly, we retrospectively reviewed the outcome of all newborn infants treated with ECMO over the past 21 years at a single center.
Methods
This study was conducted at Kagoshima City Hospital Neonatal Intensive Care Unit after receiving approval from the institutional review board of Kagoshima City Hospital.
Retrospective medical charts were reviewed for all newborn infants treated with ECMO during the 21 year study period between January 1995 and December 2015. ECMO was applied in newborn infants meeting all of following three criteria: (i) severe respiratory failure defined as oxygenation index (OI) >20 with lack of improvement despite > 12 h of conventional treatment, including high frequency ventilation (since 1988), use of inhaled nitric oxide (since 1994), and use of catecholamine with or without volume loading; (ii) treatable etiology of respiratory failure; and (iii) high mortality risk > 50% anticipated without the use of ECMO. Exclusion criteria included untreatable causes of respiratory failure (such as congenital tracheal stenosis), bleeding diathesis associated with subgaleal hemorrhage, and severe congenital malformations. OI was calculated using the following equation: OI = FiO 2 9 mean airway pressure (cm) 9 100/post-ductal PaO 2 .
Information collected from medical charts included gestational age (GA, weeks) at birth, birthweight, Apgar scores at 1 and 5 min, underlying etiology for respiratory failure, cannulation mode for ECMO (veno-venous [VV] or veno-arterial [VA]), adverse events associated with ECMO, and survival to hospital discharge (SHD). Early ECMO was defined as use of ECMO within 24 h after birth.
ECMO
Vascular access was achieved by cannulation of the neck of neonates under open surgical procedure with general anesthesia. In cases of VV, single-and double-lumen catheters were inserted into the internal jugular vein cephalad and proximal (heart side) with catheter tip at the atrium, respectively, allowing drainage of blood from the both sides and blood return to the atrium. In cases of VA, two single-lumen catheters were inserted into the internal jugular vein: one each cephalad and proximal (heart side), allowing drainage of blood from both sides. Another single-lumen catheter was inserted into the internal carotid artery proximal (heart side) with the catheter tip at the aortic arch, allowing blood return to the aorta for the purpose of not only respiratory support but also circulatory support for infants with depressed cardiac function. Therefore, VA mode was preferred in patients with circulatory problems, such as hypotension and low cardiac motility on ultrasound. VV blood flow rate of 60-80 mL/kg/ min and VA blood flow rate of 80-100 mL/kg/min were used. Nafamostat mesilate was used for anticoagulation, and activated clotting time 200-250 s was maintained. Monitors were designed to measure circuit function and to alert the operator to abnormal conditions using four pressure sensors installed within the circuit.
Statistical analysis
Data are presented as median (range). Statistical analysis was performed using JMP10© statistical software package (SAS, Cary, NC, USA). The Wilcoxon/Kruskal-Wallis method was used for comparison of medians. Fisher's exact probability test was used for comparison of categorical variables. Stepwise logistic regression analysis was performed to determine independent determinant factors for SHD. In all analyses, P < 0.05 was taken to indicate statistical significance.
Results
A total of 61 newborn infants underwent ECMO during the study period. No specific adverse events ascribed to ECMO occurred in the 61 infants. Of the 61 infants, 35 (57%) had SHD and the remaining 26 (43%) had adverse outcome, that is, died before hospital discharge (Table 1 ). GA at birth was significantly higher for SHD infants than for those with adverse outcome (Table 1 ; Fig. 1 ), but birthweight and Apgar score did not differ significantly between the two groups.
Underlying etiology of respiratory failure included CDH (n = 16), meconium aspiration syndrome (MAS, n = 14), persistent pulmonary hypertension of the newborn (PPHN, n = 8) associated with hypoxic ischemic encephalopathy (HIE), sepsis (n = 7), emphysema (n = 5), and congenital heart disease (CHD, n = 4), and others (n = 7; Table 1 (Table 1) . Procedures for ECMO did not change over time. Although most background factors did not change significantly over time, the proportion of MAS infants appeared to decrease from 27% (11/ 41) in period A to 15% (3/20) in period B (P = 0.353; data not shown). ECMO was considered a determinant factor for SHD, but the SHD rate did not differ significantly between period A and period B (51%, 21/41 vs 70%, 14/20; P = 0.182).
The SHD rate according to etiology was as follows: CDH, 31% (5/16); MAS, 86% (12/14); PPHN with HIE, 75% (6/8); sepsis, 43% (3/7); emphysema, 80% (4/5); CHD, 25% (1/4); and others, 57% (4/7). Number of days with ECMO was significantly lower for infants with than without SHD ( Table 1) . The SHD rate was significantly higher for infants with than without early ECMO (72%, 28/39 vs 32%, 7/22, respectively; P = 0.003), and for those with than without VV mode (78%, 18/23 vs 45%, 17/38, respectively; P = 0.016; Table 1 ; Fig. 2 ). As many as 94% (15/16) of infants with both early ECMO and VV mode achieved SHD, while only 27% (4/15) of those with neither early ECMO nor VV mode did so (P = 0.000; Fig. 2) .
No optimal cut-offs were identified for differentiation of infants with and without SHD on receiver operating characteristic curve analysis using continuous variables of GA at birth, birthweight and number of days of ECMO. SHD rate, however, was 61% (33/54) vs 29% (2/7; P = 0.030, Fisher's exact test), for term (GA ≥ 37 weeks) and preterm infants, respectively; 64% (33/52) vs 22% (2/9; P = 0.125), for those with birthweight ≥2500 g and <2500 g, respectively; and 67% (29/43) vs 33% (6/18; P = 0.022), for those with ECMO duration <8 days and ≥8 days, respectively. Stepwise logistic regression analysis (Wald) was then carried out after entering seven factors: birthweight ≥2500 g (yes, no), GA at birth ≥37 weeks (yes, no), presence of CDH (yes, no), presence of MAS (yes, no), VV cannulation (yes, no), early ECMO (yes, no), and ECMO duration <8 days (yes, no). Two independent factors of SHD were identified: early ECMO (OR, 9.63; 95% CI: 2.47-37.6), and ECMO duration <8 days (OR, 8.05; 95% CI: 1.94-33.5).
The SHD rate was 88% (23/26) for infants with early ECMO and ECMO duration <8 days. In the two groups divided according to use of early ECMO, only the ratio of birthweight ≥2500 g differed significantly between infants with vs without early ECMO (95%, 37/39 vs 68%, 15/22, respectively). In the two groups divided according to ECMO duration <8 days, only ratio of CDH differed significantly between infants with vs without ECMO duration <8 days (14%, 6/43 vs 56%, 10/18, respectively). Although birthweight CDH, congenital diaphragmatic hernia; CHD, congenital heart diseases; ECMO, extracorporeal membrane oxygenation; HIE, hypoxic ischemic encephalopathy; MAS, meconium aspiration syndrome; PPHN, persistent pulmonary hypertension of the newborn; SHD, survival to hospital discharge;VA, veno-arterial; VV, veno-venous. Fig. 2 Schematic diagram of association between early extracorporeal membrane oxygenation (ECMO), veno-venous (VV) vascular access mode, and survival to hospital discharge (SHD) rate. Group A: meconium aspiration syndrome (MAS), n = 5; persistent pulmonary hypertension of the newborn (PPHN) with hypoxic ischemic encephalopathy (HIE), n = 4; emphysema, n = 3; congenital heart disease, n = 1; other, n = 2. Group B: congenital diaphragmatic hernia (CDH), n = 4; MAS, n = 6; sepsis, n = 2; other, n = 1. Group C: MAS, n = 1; emphysema, n = 1; other, n = 1. Group D, CDH, n = 1; PPHN with HIE, n = 2; sepsis, n = 1.
≥2500 g and CDH were confounding factors in this study, SHD rate was 91% (20/22) for infants without CDH, but with birthweight ≥2500 g, early ECMO, and ECMO duration <8 days.
Discussion
This study demonstrated that among newborn infants treated with ECMO, SHD was likely to occur in those treated with ECMO within 24 h after birth and in those with early weaning from ECMO (ECMO duration <8 days). Organ dysfunction score before ECMO is correlated with survival in adult patients with acute respiratory distress syndrome (ARDS). 7 Late ECMO and after age 7 days is a risk factor for adverse outcome of neonatal ECMO. 8 Given that recovery from became difficult with increasing time of hypoxemia, ECMO was initiated early (within 24 h after birth) in 64% (39/61) of newborn infants when they were refractory to conventional treatment in this study. Although not in the field of neonatal intensive care, there are promising data for the early use of ECMO in acute hypoxemic respiratory failure, cardiac arrest, and cardiogenic shock. 9 For example, a literature review on the effects of ECMO on SHD rate in patients with influenza (H1N1) infection concluded that "ECMO is feasible and effective in patients with acute lung injuries due to H1N1 infection." 10 In a prospective observational study on the use of ECMO for patients aged 18-75 years with in-hospital cardiac arrest of cardiac origin undergoing cardiopulmonary resuscitation (CPR) >10 min compared with conventional CPR, 11 CPR with ECMO had both short-and long-term survival benefits over conventional CPR. In a retrospective review of 65 patients with severe ARDS treated with ECMO, 31 survivors (48%) had shorter duration of mechanical ventilation before ECMO (53 vs 112 h). 7 In the present study, early ECMO within 24 h after birth was associated with a higher SHD rate (72%, 28/39 among early ECMO users vs 32%, 7/22 among non-early ECMO users) and was an independent factor of SHD; those with early ECMO had a 9.6-fold higher chance of SHD independently of other factors. This supported our policy, that is, the early use of ECMO when refractory to conventional treatment.
In the present study, VV and VA modes were used in 38% and in 62% of 61 newborn infants, respectively and the SHD rate was significantly higher in the former than in the latter (78%, 18/23 vs 45%, 17/38, respectively), consistent with the 2012 ESLO registry report in which VA was the predominant mode (72%) in neonatal ECMO, with a higher survival rate in VV than VA mode of ECMO for respiratory failure (84% vs 71%, respectively). 5 Vascular access mode, however, was a confounding factor and not an independent risk factor for SHD in the present study.
In the present study, GA at birth was significantly higher for infants with than without SHD, consistent with a previous report by Ramachandrappa et al. 12 in which 2135 late preterm (GA at birth, 34-0/7-36-6/7), 3119 early term (37-0/7-38-6/7), and 9274 full-term (39-0/7-42-6/7) infants registered at the ELSO from January 1986 to December 2006 were analyzed. GA at birth was a highly significant predictor of mortality, with mortality rates of 26%, 18%, and 11% for late preterm, early term, and full-term, respectively. 12 In addition, late preterm infants had a longer duration of ECMO, partly consistent with the present results, although the number of days with ECMO was not specified in that report. 12 In the present study, the number of days with ECMO was significantly lower in SHD infants than in those with adverse outcome (4.0 vs 5.5 days, respectively). The average was reported as 7 days in a 2012 ELSO registry report. 5 On multivariate logistic regression analysis, short ECMO duration <8 days, but not term delivery, was an independent determinant for SHD in this study: those with ECMO duration <8 days had an 8.0-fold higher chance of SHD independently of other factors.
In the present series of ECMO patients, overall SHD rate was 57% (35/61), somewhat poorer than that of 68% (21448/ 31327) in the neonatal ECMO registered at the ELSO through July 2012. This was mainly due to the poorer outcome of the present CDH infants compared with the 2012 ELSO registry report: SHD rate was only 31% (5/16) for CDH in the present study, while it was approximately 50% in the 2012 ELSO registry report. 5 Among newborn Japanese CDH infants treated with ECMO, survival >90 days after birth was reported in 37% (16/37) of isolated CDH infants without other anomalies, 6 consistent with the 36% (5/14) in the present study. This suggests that revision of indications for ECMO in CDH is required in Japan. The present SHD rates for MAS (86%, 12/ 14) and PPHN with HIE (75%, 6/8) were similar to those in the ELSO report (94% and 77%, respectively). 5 Despite being associated with the best outcome, use of ECMO for MAS was shown to have decreased in the ELSO report, 5 as well as in the present study. This may have been due to improvements in ventilatory technique, equipment, and therapeutics. 13, 14 Herein we have reported on ECMO in 61 newborn Japanese infants born during the 21 year period from January 1995. The overall SHD rate was unsatisfactory, 57% (35/61), mainly due to the poorer outcome for CDH, which had a low SHD rate of 31% (5/16). The SHD rates of 86% (12/14) for MAS, 75% (6/8) for PPHN with HIE, and 80% (4/5) for emphysema, however, were similar to those in the 2012 ELSO registry report. 5 We emphasize that the early use of ECMO within 24 h after birth was effective in leading to SHD independently of other factors, and that infants requiring ECMO >7 days were less likely to have SHD, independently of other factors.
